Symbols

CRMD

CorMedix·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CRMD

Cormedix Inc.

A biopharmaceutical company developing therapeutic products for cardiovascular and renal diseases

Industry

Pharmaceutical

Established Date

07/28/2006

Listing Date

02/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

191

Fiscal Year Ends

12-31

Website

www.cormedix.com

Security Type

Common stock

Office address

389 Interpace Pkwy, Suite 450, Parsippany, NJ 07054

Business

Introduction

CorMedix Inc., was incorporated in Delaware on July 28, 2006. The Company is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the prevention and treatment of life-threatening diseases and conditions. The company's main focus is the commercialization of its lead product, DefenCath, in the United States. The company has licensed the development and commercialization of DefenCath worldwide. The name DefenCath is an American proprietary name approved by the U.S. Food and Drug Administration (FDA).

Company Financials

EPS

CRMD has released its 2025 Q4 earnings. EPS was reported at 0.61, versus the expected 0.83, missing expectations. The chart below visualizes how CRMD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRMD has released its 2025 Q4 earnings report, with revenue of 128.62M, reflecting a YoY change of 312.10%, and net profit of 14.02M, showing a YoY change of 4.13%. The Sankey diagram below clearly presents CRMD's revenue sources and cost distribution.